Issue Date: February 27, 2012
Enanta Signs Novartis For Hepatitis Drug
Enanta Pharmaceuticals, a specialist in small-molecule drugs for infectious diseases, has entered a pact with Novartis for development, manufacture, and commercialization of its lead candidate, EDP-239, which comes from its NS5A hepatitis C virus inhibitor program. Enanta will receive an up-front payment of $34 million and is eligible for up to $406 million in milestone payments. NS5A is a nonstructural viral protein that is essential to viral replication. The protein has emerged as an important target for antiviral drug development, Enanta says.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society